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Only One Fifth of the Sudden Cardiac Arrest Victims 
in the Community are Eligible for a Primary 
Prevention ICD Before the Event, but Among These, a 
Small Proportion (13%) are Actually Implanted  
According to data from the Oregon Sudden Unexpected 
Death study, among 2093 victims of sudden cardiac arrest 
(SCA) over a decade, of 448 having information about left 
ventricular ejection fraction (LVEF), 92 (20.5%) were 
eligible for primary ICD implantation, 304 (67.9%) were 
ineligible because of LVEF>35%, & the remainder (52, 
11.6%) had LVEF ≤35% but were ineligible on the basis 
of clinical criteria. Among eligible subjects, only 12 (13%) 
received a primary ICD. Compared with recipients, ICD 
nonrecipients were older (age at LVEF assessment, 
67.1±13.6 vs 58.5±14.8 years, P=0.05), with 20% aged ≥
80 years (vs 0% among recipients, P=NS). Additionally, a 
subgroup (26%) had either a clinical history of dementia 
or were undergoing chronic dialysis. The authors 
concluded that only one fifth of the SCA cases in the 
community were eligible for a primary prevention ICD 
before the event, but among these, a small proportion 
(13%) were actually implanted. Although older age and 
comorbidity may explain nondeployment in a subgroup of 
these cases, other determinants such as socioeconomic 
factors, health insurance, patient preference, and clinical 
practice patterns may play a role (Narayanan K, et al, 
Circulation 2013;128:1733-1738).  
 
Appropriate ICD Therapies over 10 Years are More 
Prevalent in Symptomatic Brugada Syndrome (19-
48%) but Still Occur in Asymptomatic Patients (12%) 
A total of 378 patients (310 men; aged 46±13 years) 
with a type 1 Brugada ECG pattern were implanted with 
an implantable cardioverter-defibrillator-ICD; 31 for 
aborted sudden cardiac arrest, 181 for syncope, and 166 
asymptomatic. During a mean follow-up of 77±42 months 
for 363 patients, 7 patients (2%) died (1 as a result of an 
inappropriate shock), and 46 patients (12%) had 
appropriate device therapy (5±5 shocks per patient). 
Appropriate device therapy rates at 10 years were 48% for 
patients whose ICD indication was aborted sudden cardiac 
arrest, 19% for those with syncope, and 12% for the 
asymptomatic patients. At 10 years, rates of inappropriate 
shock and lead failure were 37% and 29%, respectively. 
Inappropriate shock occurred in 91 patients (24%) because 
of lead failure (n=38), supraventricular tachycardia 
(n=20), T-wave oversensing (n=14), or sinus tachycardia 
(n=12). Reduced inappropriate shocks were noted with 
introduction of remote monitoring, programming a high 
single ventricular fibrillation zone (>210–220 bpm), and a 
long detection time. The authors concluded that 
appropriate therapies are more prevalent in symptomatic 
Brugada syndrome but are not insignificant in asymptoma-
tic patients (1%/y). Optimal ICD programming and remote 
monitoring dramatically reduce inappropriate shocks. 
However, lead failure remains a major problem in this 
population (Sacher F et al, Circulation 2013;128: 1739-1747).  
 
Complex Antithrombotic Therapy Prescribed to 
Elderly Patients Increases the Risk of Gastrointestinal 
Bleeding  
Among 78,133 veterans (98.6% white; mean age 
72.3+7.7), 64% were prescribed aspirin(ASA)-antiplatelet 
and anticoagulant-antiplatelet and 6% were prescribed 
triple therapy (anticoagulant-antiplatelet-ASA). The 
incidence of upper gastro-intestinal (GI) bleeding was 
20.1/1000 patient-years, and the incidence of lower GI 
bleeding was 70.1/1000 patient-years. ASA-anticoagulant 
and triple therapy were associated with the highest 
incidence of transfusion and hospitalization. A 40%-60% 
increased risk of upper GI bleeding was observed with all 
strategies. Lower GI bleeding was 30% higher with anti-
coagulant-antiplatelet, and transfusion increased with 
ASA-anticoagulant (hazard ratio-HR, 6.1) and triple 
therapy (HR, 5.0). Increased risk of hospitalization was 
noted with all strategies. The number needed to harm for 
upper or lower GI bleeding ranged from 52-65 & 15-23, 
respectively. The number needed to harm for hospitaliza-
tion was 39 (anticoagulant-antiplatelet), 34 (ASA-anti-
coagulant), 67 (ASA-antiplatelet), and 45 (triple therapy) 
patients. The authors concluded that among elderly 
patients, complex antithrombotic therapy-related lower 
and upper GI bleeding events are clinically relevant risks 
resulting in increased hospitalizations and transfusions 
(Abraham NS, et al, Circulation 2013;128: 1869-1877).  
 
POST Trial: Negative Results for Ischemic 
Postconditioning During Primary PCI  
In the POST (Postconditioning on Myocardial 
Reperfusion in Patients With STEMI) trial, a total of 700 
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patients undergoing primary percutaneous coronary 
intervention (PCI) for ST–elevation myocardial infarction 
(STEMI) within 12 hours after symptom onset were 
randomly assigned to the conventional primary PCI group 
or to the postconditioning group (balloon positioned at the 
culprit lesion was inflated 4 times for 1 min with low 
pressure inflations at <6 atm, each separated by 1 min of 
deflation). Complete ST resolution occurred in 40.5% of 
patients in the post-conditioning group and 41.5% of 
patients in the conventional PCI group (P=NS). The rate of 
myocardial blush grade of 0 or 1 and the rate of major 
adverse cardiac events (a composite of death, MI, severe 
heart failure, or stent thrombosis) at 30 days did not differ 
significantly between the postconditioning group and the 
conventional PCI group (17.2% vs 22.4% and 4.3% vs 
3.7%, respectively; P=NS). The authors concluded that 
ischemic postconditioning did not improve myocardial 
reperfusion in patients with STEMI undergoing primary 
PCI (Hahn J-Y, Circulation 2013;128:1889-1896).  
 
Patients With Normal Flow/Low Gradient Severe 
Aortic Stenosis With Preserved Ejection Fraction Have 
Favorable Survival With Medical Management, and 
the Impact of Surgery on Survival is Neutral  
Among 1704 severe aortic stenosis (AS) patients with 
aortic valve area <1 cm2 and preserved ejection fraction 
(≥50%), those with normal flow (>35mL/m2)/low gradient 
(<40 mm Hg) (n=352, 21%) had favorable survival with 
medical management (2-year estimate, 82% vs 67% in 
normal flow/high grade; P<0.0001). Low flow/low 
gradient severe AS (n=53, 3%) was characterized by lower 
ejection fraction, more prevalent atrial fibrillation and 
heart failure, reduced arterial compliance, and reduced 
survival (2-year estimate, 60% vs 82% in normal flow/high 
gradient; P<0.001). In multivariable analysis, the low flow 
/low gradient pattern was the strongest predictor of 
mortality (hazard ratio-HR, 3.26; P<0.001 vs normal 
flow/low gradient). Aortic valve replacement was 
associated with a 69% mortality reduction (HR, 0.31; 
P<0.0001) in low flow/low gradient and normal flow/high 
gradient, with no survival benefit associated with aortic 
valve replacement in normal flow/low gradient and low 
flow/ high gradient. The authors concluded that normal 
flow/low gradient severe AS with preserved ejection 
fraction exhibits favorable survival with medical 
management, and the impact of aortic valve replacement 
on survival was neutral. Low flow/low gradient severe AS 
is characterized by a high prevalence of atrial fibrillation, 
heart failure, and reduced survival, and aortic valve 
replacement was associated with improved survival (Eleid 
MF, et al, Circulation 2013;128:1781-1789). 
 
Similar Benefit from TAVI of Patients With Low-Flow, 
Low-Gradient, Severe AS and either Normal or Low 
Ejection Fraction With Those With High-Gradient AS 
A total of 208 TAVI patients had high-mean gradient 
(MG >40 mmHg) severe aortic stenosis (AS) (HG-AS), 85 
had ‘paradoxical’ low-flow, low-gradient PLF-LG (MG ≤ 
40 mmHg, aortic valve area - AVA ≤0.6 cm2 m−2, stroke 
volume index ≤35 mL/m2, ejection fraction-EF ≥50%), and 
61 had low-flow low-gradient (LEF-LG; MG ≤ 40 mmHg, 
AVA ≤0.6 cm2 m−2, EF ≤40%). Compared with HG-AS, 
PLF-LG and LEF-LG had higher systemic vascular 
resistances but lower valvulo-arterial impedances. At 30 
days, no differences in cardiac death (~5-6.5%) or death 
(~6-8.4%) were observed among the 3 groups. At 1 year, 
functional improvement occurred in most surviving 
patients (HG-AS: 69.2% vs. PLF-LG: 71.7% vs. LEF-LG: 
89.3%, P=0.09) and no significant differences in overall 
mortality were observed (~17.5-24.5%, P=NS). Compared 
with HG-AS, LEF-LG had a higher 1 year cardiac 
mortality (hazard ratio 2.45, P=0.04). The authors 
concluded that TAVI in PLF-LG or LEF-LG patients is 
associated with overall mortality rates comparable with 
HG-AS patients and all groups have similar benefit 
(O'Sullivan CJ et al, Eur Heart J 2013; 34: 3437-3450).  
 
National Australian Childhood Cardiomyopathy (CM) 
Study: The Highest-Risk Period for Children With 
Dilated CM is in the First Year After Diagnosis (26% 
Compared With ~1% per Year in Subsequent Years)  
Among 175 patients 0 to <10 years of age at time of 
diagnosis of dilated cardiomyopathy (DCM), survival free 
from death or transplantation was 74% 1 year after 
diagnosis, 62% at 10 years, and 56% at 20 years. In 
multivariable analysis, age at diagnosis <4 weeks or >5 
years, familial CM, and lower baseline left ventricular 
(LV) systolic function were associated with increased risk 
of death or transplantation. At 15 years after diagnosis, 
echocardiographic normalization had occurred in 69% of 
surviving patients. Children with lymphocytic myocarditis 
had better survival and a higher rate of echocardiographic 
normalization. At the latest follow-up, 100 of 104 of 
survivors (96%) were free of cardiac symptoms, and 83 
(80%) were no longer receiving pharmacotherapy. The 
authors concluded that death or transplantation occurred in 
26% of patients with childhood DCM within 1 year of 
diagnosis and ~1% per year thereafter. Risk factors for 
death or transplantation include age at diagnosis, familial 
CM, and severity of LV dysfunction. The majority of 
surviving patients are well and free of cardiac medication 
(Alexander PM et al, Circulation 2013;128: 2039-2046).  
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Analysis of 93 801 Procedures of Catheter Ablation of 
Atrial Fibrillation in the United States (2000 – 2010): 
Major Complication Rates Steadily Increasing 
An estimated 93,801 AF ablations were performed 
from 2000 to 2010 in the US. The overall frequency of in-
hospital complications was 6.29% with combined cardiac 
complications (2.54%) being the most frequent. Cardiac 
complications were followed by vascular (1.53%), 
respiratory (1.3%), and neurological complications 
(1.02%). The in-hospital mortality was 0.46%. Annual 
operator (<25 procedures) and hospital volume (<50 
procedures) were significantly associated with adverse 
outcomes. There was a small, albeit non-significant, rise in 
overall complication rates. The authors concluded that 
overall complication rate was 6.29% in patients 
undergoing AF ablation. There was a significant 
association between operator and hospital volume and 
adverse outcomes (Deshmukh A et al, Circulation 2013; 
128:2104-2112).  
 
Favorable Effect of a PCSK9 Monoclonal Antibody in 
Homozygous Familial Hypercholesterolemia  
A small number (n=8) of patients with homozygous 
familial hypercholesterolemia on stable drug therapy were 
treated with subcutaneous 420 mg Evolocumab/AMG 145 
(monoclonal antibody to proprotein convertase 
subtilisin/kexin 9 - PCSK9) every 4 weeks for ≥12 weeks, 
followed by 420 mg every 2 weeks for an additional 12 
weeks. Mean change from baseline in LDL cholesterol at 
week 12 was −16.5% (P=NS) and −13.9% (P=NS) with 4- 
and 2-week dosing, respectively. No reduction was seen in 
the 2 LDL receptor-negative patients. Over the treatment 
periods, mean LDL cholesterol reductions in the 6 LDL 
receptor–defective patients were 19.3±16% and 26.3±20% 
with 4- and 2-week dosing, respectively (P=0.03 for both 
values). There were no serious side effects. The authors 
concluded that evolocumab produced significant and dose-
related LDL cholesterol lowering in homozygous familial 
hypercholesterolemia patients with defective LDL 
receptor activity but no reduction in those who were 
receptor negative (Stein EA et al, Circulation 2013;128: 
2113-2120).  
 
Baseline Mitral Regurgitation >Mild is Associated 
With Higher Mortality After Corevalve–TAVI 
Among 1007 consecutive patients undergoing 
Corevalve transcatheter aortic valve implantation (TAVI), 
670 (66.5%) had no/mild, 243 (24.1%) moderate, and 94 
(9.3%) severe mitral regurgitation (MR). At 1 month after 
TAVI, patients with severe or moderate MR showed 
similar mortality rates, but both were higher compared 
with patients with mild/no MR (odds ratio-OR, 2.2 & 1.9, 
respectively; P<0.05). One-year mortality was also similar 
between patients with severe and those with moderate MR 
(hazard ratio-HR, 1.4; P=0.06) and still higher compared 
with patients with mild/no MR (HR, 1.7; P<0.001; & HR, 
1.4; P=0.03, respectively). Severe pulmonary 
hypertension, atrial fibrillation (AF), and MR > mild, but 
not an improvement of ≥1 grade in MR severity, were 
independent predictors of mortality at 1 year. At 1 year, an 
improved MR was observed in 47% of patients with severe 
and 35% with moderate MR. Functional MR and absence 
of severe pulmonary hypertension and AF independently 
predicted the improvement in MR severity. The authors 
concluded that baseline MR >mild is associated with 
higher mortality after CoreValve–TAVI. A significant 
improvement in MR was more likely in patients with 
functional MR and without severe pulmonary 
hypertension or AF. The improvement in MR did not 
independently predict mortality (Poli A et al, Circulation 
2013;128:2145-2153).  
 
PARTNER A Trial: Transcatheter Aortic Valve 
Implantation (TAVI) May be a Reasonable Option in 
Select Patients with Concomitant Mitral Valve Disease 
Among the PARTNER A trial patients with severe, 
symptomatic aortic stenosis undergoing either 
transcatheter (TAVI) (n=331) or surgical aortic valve 
replacement (AVR) (n=299), moderate or severe mitral 
regurgitation (MR) was reported at baseline in 65 TAVI 
patients (19.6%) and 63 surgical patients (21.2%). At 30 
days, among survivors who had isolated AVR/TAVI, 
moderate/severe MR had improved in 25 AVR patients 
(69%) and 30 TAVI patients (58%), was unchanged in 10 
AVR patients (28%) and 19 TAVI patients (36.5%), and 
worsened in 1 AVR patient (3%) and 4 TAVI patients (6%; 
P=NS). Mortality at 2 years was higher in AVR patients 
with moderate or severe MR than in those with mild or less 
MR (50% vs 28%; hazard ratio-HR, 1.73; P=0.04). In 
contrast, MR severity at baseline did not affect mortality 
in TAVI patients (37% vs 33%, moderate/severe vs 
none/mild; HR, 1.14; P=0.58). The authors concluded that 
both TAVI and AVR were associated with a significant 
early improvement in MR in survivors. However, 
moderate or severe MR at baseline was associated with 
increased 2-year mortality after AVR but not after TAVI. 
TAVI may be a reasonable option in selected patients with 
concomitant mitral valve disease (Barbanti M et al, 
Circulation 2013;128:2776-2784).  
 
Automated External Defibrillators Inaccessible to 
>50% of Cardiac Arrests in Public Locations During 
Evening, Nighttime, and Weekends  
Of 1864 cardiac arrests in public locations in 
Copenhagen, Denmark (1994-2011), 61.8% (n=1152) 
occurred during the evening, nighttime, or weekends. Of 
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552 registered automated external defibrillators (AEDs), 
9.1% (n=50) were accessible at all hours, and 96.4% 
(n=532) were accessible during the daytime on all 
weekdays. Regardless of AED accessibility, 28.8% (537 of 
1864) of all cardiac arrests were covered by an AED. 
Limited AED accessibility decreased coverage of cardiac 
arrests by 4.1% (9 of 217) during the daytime on weekdays 
and by 53.4% (171 of 320) during the evening, nighttime, 
and weekends. The authors concluded that limited AED 
accessibility at the time of cardiac arrest decreased AED 
coverage by 53.4% during the evening, nighttime, and 
weekends, which is when 61.8% of all cardiac arrests in 
public locations occurred. Thus, attention is warranted not 
only at strategic placement but also at uninterrupted AED 
accessibility, if public-access defibrillation is to improve 
survival after out-of-hospital cardiac arrest (Hansen CM et 
al, Circulation 2013;128:2224-2231).  
 
Patients with Major Bleeding on Dabigatran Managed 
with Supportive Care, Require More Red Cell but Less 
Plasma Transfusions, but Outcomes do not Appear 
Worse than for Warfarin  
Bleeding reports were reviewed from 1034 patients 
with 1121 major bleeds enrolled in 5 trials comparing 
dabigatran with warfarin in 27,419 patients treated for 6-
36 months. Patients with major bleeds on dabigatran 
(n=627 of 16,755) were older, had lower creatinine 
clearance, and more frequently used aspirin or non-steroid 
anti-inflammatory agents than those on warfarin (n=407 of 
10 002). The 30-day mortality after the first major bleed 
tended to be lower in the dabigatran group (9.1%) than in 
the warfarin group (13.0%; P=0.057). After adjustment for 
gender, age, weight, renal function, and concomitant 
antithrombotic therapy, the odds ratio for 30-day mortality 
with dabigatran vs warfarin was 0.66 (P=0.051). Major 
bleeds in dabigatran patients required more blood 
transfusions (423/696, 61%) than bleeds in warfarin 
patients (175/425, 42%; P<0.001) but less frequently 
plasma (dabigatran, 19.8%; warfarin, 30.2%; P<0.001). 
Dabigatran patients with a bleed had shorter stay in the 
intensive care unit (mean 1.6 nights) compared with 
warfarin patients (mean 2.7 nights; P=0.01). The authors 
concluded that patients who experienced major bleeding 
on dabigatran required more red cell but less plasma 
transfusions, required a shorter stay in intensive care, and 
had a trend to lower mortality compared with those who 
had major bleeding on warfarin (Majeed A et al, 
Circulation 2013;128:2325-2332). 
 
Active Myocarditis: Left Ventricular Dysfunction at 
Baseline Defines a Subgroup of Patients Characterized 
by Poorer Long-Term Prognosis  
From 1981 to 2009, 82 patients with biopsy-proven 
active myocarditis were followed-up for 147±107 months. 
At baseline, left ventricular dysfunction (LVEF<50%) and 
left atrium enlargement were independently associated 
with long-term heart transplantation–free survival, 
regardless of the clinical pattern of disease onset. At 6 
months, improvement/normalization of LVEF was 
observed in 53% of patients. Persistence of NYHA III-IV 
classes, left atrium enlargement, and improvement/ 
normality of LVEF at 6 months emerged as independent 
predictors of long-term outcome. The authors concluded 
that baseline LV function is a marker for prognosis; its 
reassessment at 6 months appears useful for assessing 
longer-term outcome (Anzini M et al, Circulation 
2013;128:2384-2394).   
 
Heart Failure Hospitalization Within 1 Year After 
Acute MI Remains a Marker of High-Risk, With 
Nearly Half of Patients Dying Within a Year After the 
Development of Heart Failure  
Among 2 789 943 acute myocardial infarction (AMI) 
hospitalizations of Medicare beneficiaries (1998-2010), 
the number of patients hospitalized for heart failure (HF) 
within 1 year after AMI declined modestly from 16.1 per 
100 person-years in 1998 to 14.2 per 100 person years in 
2010 (P<0.001). After adjusting for demographic factors, 
a relative 14.6% decline for HF hospitalizations after AMI 
was observed. Unadjusted 1-year mortality following HF 
hospitalization after AMI was 44.4% in 1998, which 
decreased to 43.2% in 2004 to 2005, but then increased to 
45.5% by 2010. After adjusting for demographic factors 
and clinical comorbidities, this represented a 2.4% relative 
annual decline (hazard ratio-HR, 0.976) from 1998 to 
2007, but a 5.1% relative annual increase from 2007 to 
2010 (HR, 1.051). The authors concluded that among 
Medicare beneficiaries, HF hospitalization after AMI 
decreased by ~14% from 1998 to 2010, which may 
indicate improvements in the management of AMI. In 
contrast, survival after HF following AMI remains poor, 
and has worsened (~5%) from 2007 to 2010, 
demonstrating that challenges still remain for the treatment 
of this high-risk condition after AMI (Chen J et al, 
Circulation 2013;128:2577-2584).   
 
Hypertophic Cardiomyopathy (HCM): an Abnormal 
High-Sensitivity Cardiac Troponin T (hs-cTnT) is an 
Independent Predictor of Adverse Outcome 
Of 183 HCM patients, 99 (54%) had abnormal hs-cTnT 
values (>14 pg/ml). During a mean follow-up of 4.1 + 2.0 
years, 32 (32%) of these 99 patients, and only 6 (7%) of 84 
patients with normal hs-cTnT values, experienced 
cardiovascular (CV) events (CV deaths, heart failure 
admissions, sustained ventricular tachycardia, embolic 
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events, and progression to New York Heart Association 
functional class III or IV status) (hazard ratio -HR: 5.05, p 
< 0.001). After multivariate analysis, abnormal hs-cTnT 
value remained an independent predictor of CV events 
(HR: 3.23, p = 0.012). In the abnormal hs-cTnT group, 
overall risk increased with an increase in hs-cTnT value. 
The authors concluded that in patients with HCM, an 
abnormal hs-cTnT is an independent predictor of adverse 
outcome, and a higher degree of abnormality in hs-cTnT 
value is associated with a greater risk of CV events (Kubo 
T et al, J Am Coll Cardiol 2013;62:1252–1259).  
 
MADIT-CRT: in Patients with Mild Heart Failure and 
a CRT-D or ICD Device, Carvedilol Conferred a 36% 
Reduction in Inappropriate ATP and Shock Therapy 
Compared with Patients Receiving Metoprolol 
Among patients in the MADIT-CRT study who 
received a cardiac resynchronization therapy (CRT) 
defibrillator (CRT-D) or an implantable cardioverter-
defibrillator (ICD) device (N=1790), inappropriate therapy 
occurred in 253 (14%) over 3.4+1.1 years. Treatment with 
carvedilol was associated with a significantly decreased 
risk of inappropriate therapy (anti-tachycardia pacing-ATP 
or shock) compared with metoprolol (hazard ratio - HR: 
0.64; p = 0.002). The risk of inappropriate therapy caused 
by atrial fibrillation was also reduced in patients receiving 
carvedilol compared with metoprolol (HR: 0.50; p = 
0.004). The authors concluded that in heart failure patients 
receiving a CRT-D or an ICD device, carvedilol was 
associated with a 36% lower rate of inappropriate ATP and 
shock therapy compared with metoprolol. Inappropriate 
therapy due to atrial fibrillation was associated with a 50% 
lower rate in patients receiving carvedilol compared with 
those receiving metoprolol (Ruwald MH et al, J Am Coll 
Cardiol 2013;62:1343–1350).  
 
Meta-Analysis of 5 Cardiac Resynchronization 
Therapy (CRT) Trials Confirmed Benefit in Heart 
Failure (HF) Patients in Sinus Rhythm & QRS >140 ms  
Per a meta-analysis of 5 randomized trials comparing 
CRT with no active control (CARE-HF, MIRACLE, 
REVERSE) or CRT-D with ICD (REVERSE, MIRACLE 
ICD, RAFT), 3782 of 4317 patients were in sinus rhythm, 
with median age 66 years, QRS duration 160 ms, LVEF 
24%, and left bundle branch block in 78%. Per multivariate 
analysis, only QRS duration predicted the magnitude of the 
effect of CRT on outcomes. There was an increasing 
benefit with increasing QRS duration, and a high 
probability of substantial benefit from CRT when QRS 
duration exceeds 140 ms. The authors concluded that QRS 
duration is a powerful predictor of the effects of CRT on 
morbidity and mortality in patients with symptomatic HF 
and LV systolic dysfunction who are in sinus rhythm 
(Cleland JG et al, Eur Heart J 2013; 34: 3547–3556).  
 
EchoCRT Study: Cardiac-Resynchronization Therapy 
(CRT) in Heart Failure (HF) with a Narrow QRS 
Offers no Benefit and may Increase Mortality 
A total of 809 patients with NYHA class III or IV HF, 
ejection fraction of <35%, a QRS <130 ms, and 
echocardiographic evidence of LV dyssynchrony were 
randomly assigned to have CRT on or off. On March 13, 
2013, the study was stopped for futility; mean follow-up 
was 19.4 months. The primary outcome (death or first 
hospitalization for worsening HF) occurred in 116 of 404 
patients (28.7%) in the CRT group, as compared with 102 
of 405 in the control group (25.2%) (hazard ratio-HR, 1.20; 
P=0.15). There were 45 deaths in the CRT group (11.1%) 
and 26 in the control group (6.4%) (HR, 1.81; P=0.02). The 
authors concluded that in patients with HF and a QRS <130 
ms, CRT does not reduce the rate of death or 
hospitalization for HF and may increase mortality 
(Ruschitzka F et al, N Engl J Med 2013; 369:1395-1405).  
 
Meta-analysis of 18 Trials: Aspiration Thrombectomy 
During AMI is Beneficial in Reducing MACE and 
Mortality at 6-12 Months Compared with 
Conventional PCI Alone 
Acute myocardial infarction (AMI) patients 
randomized to aspiration (18 trials, n=3,936) or 
mechanical thrombectomy (7 trials, n=1,598) before PCI 
were compared with conventional PCI alone. At mean 6-
month follow-up, major adverse cardiac events (MACE) 
(risk ratio -RR: 0.76; p = 0.006) and all-cause mortality 
(RR: 0.71; p = 0.049) were significantly reduced with 
aspiration thrombectomy. Beneficial trends were noted for 
recurrent MI (p = 0.11) and target vessel revascularization 
(p = 0.06). Final infarct size and ejection fraction at 1 
month were similar. ST resolution at 60 min (RR: 1.31; p 
< 0.0001) and TIMI blush grade 3 post-procedure (RR: 
1.37; p < 0.0001) were both improved with aspiration 
thrombectomy. In contrast, there was no difference in 
almost all end-points with mechanical thrombectomy vs. 
conventional primary PCI (7 trials, n = 1,598). The authors 
concluded that in AMI, manual, but not mechanical, 
catheter aspiration, is beneficial in reducing mortality and 
MACE at 6-12 months compared with conventional 
primary PCI alone (Kumbhani DJ et al, J Am Coll Cardiol 
2013;62:1409–1418).  
 
EMPHASIS-HF Study: Eplerenone Appears Safe and 
Efficacious in Patients with Heart Failure at High Risk 
for Hyperkalemia and/or Worsening Renal Function  
Heart failure (HF) patients at high risk for 
hyperkalemia or worsening renal function (WRF) in the 
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EMPHASIS-HF trial, i.e. patients older than 75, with 
diabetes, estimated glomerular filtration rate (eGFR) <60 
ml/min/1.73 m2, and relatively low systolic blood pressure, 
but with eGFR >30 ml/min/1.73 m2 and serum potassium 
<5.0 mmol/l received eplerenone. These high-risk patient 
subgroups treated with eplerenone had an increased risk of 
potassium >5.5 mmol/l but not of potassium >6.0 mmol/l, 
and of hospitalization for hyperkalemia or discontinuation 
of study medication due to adverse events. Eplerenone was 
effective in reducing the primary endpoint (hospitalization 
for HF or cardiovascular mortality) in all subgroups. The 
authors concluded that eplerenone was both efficacious 
and safe when carefully monitored, even in subgroups at 
high risk of developing hyperkalemia or WRF (Eschalier 
R et al, J Am Coll Cardiol 2013;62:1585–1593).  
 
ALTITUDE Study: In ICD or CRT-D Patients Adverse 
Prognosis after Shock Therapy is Related to Under-
lying Arrhythmia (VT/AF) and not to the Shock Itself  
Comparing patients (n=3,809) with first shock with 
patients without a shock (n=3,630), there was an increased 
rate of mortality in those who received their first shock for 
monomorphic ventricular tachycardia (hazard ratio - HR: 
1.65, p < 0.0001), ventricular fibrillation/polymorphic 
ventricular tachycardia (HR: 2.10, p < 0.0001), and atrial 
fibrillation/flutter (HR: 1.61, p = 0.003). In contrast, 
mortality after first shocks due to sinus tachycardia and 
supraventricular tachycardia (HR: 0.97, p = NS) and 
noise/artifact/oversensing (HR: 0.91, p = NS) was 
comparable to that in patients without a shock. The authors 
concluded that compared with no shock, those who 
received their first shock for ventricular rhythms and atrial 
fibrillation had an increased risk of death with no 
difference noted for shocks due to sinus tachycardia or 
noise/artifact/oversensing (Powell BD et al, J Am Coll 
Cardiol 2013;62:1674–1679). 
 
Wearable Cardioverter-Defibrillator Protects High-
Risk Patients Early Post-Myocardial Infarction while 
Waiting for an ICD 
For the mandatory ICD implantation waiting time post-
myocardial infarction (MI) of either 40 days or 3 months 
(for those revascularized), a wearable cardioverter-
defibrillator (WCD) was provided in 8453 patients (2005-
2011). A total of 133 patients (1.6%) received 309 
appropriate shocks. Of these patients, 91% were 
resuscitated from a ventricular arrhythmia. For shocked 
patients, the left ventricular ejection fraction (LVEF) was 
<30% in 106, 30-35% in 17, >36% in 8, and not reported 
in 2 patients. Of the 38% of patients not revascularized, 
84% had a LVEF <30%; of the 62% of patients 
revascularized, 77% had a LVEF <30%. The median time 
from the index MI to WCD therapy was 16 days. Of the 
treated patients, 75% received a shock in the first month, 
and 96% within the first 3 months of use. Shock success 
resulting in survival was 84% in nonrevascularized and 
95% in revascularized patients. The authors concluded that 
during the 40-day and 3-month waiting periods in patients 
post-MI, the WCD successfully treated sudden cardiac 
arrest in 1.4%, and the risk was highest in the first month 
of WCD use (Epstein AE et al, J Am Coll Cardiol 
2013;62:2000–2007).  
 
Non-Receivers of Pre-Procedural Aspirin are More 
Likely to Experience Adverse Outcomes of PCI 
(Higher Rate of In-Hospital Death and Stroke) 
Among 65,175 patients, 4640 (7.1%) did not receive 
aspirin within 24 h before undergoing PCI. Aspirin non-
receivers were more likely to have had previous 
gastrointestinal bleeding or to present with cardiogenic 
shock or after cardiac arrest. Absence of aspirin before PCI 
was associated with a higher rate of death (3.9% vs. 2.8%; 
odds ratio-OR: 1.89, p < 0.001) and stroke (0.5% vs. 0.1%; 
OR: 4.24, p = 0.007) with no difference in need for 
transfusions. The authors concluded that a significant 
number of patients do not receive aspirin before 
undergoing PCI. Lack of aspirin before PCI was associated 
with increased in-hospital mortality and stroke (Kenaan M 
et al, J Am Coll Cardiol 2013;62:2083–2089).  
 
Added Autonomic Denervation Enhances Pulmonary 
Vein Isolation (PVI) for Paroxysmal Atrial Fibrillation 
A total of 242 patients with paroxysmal atrial 
fibrillation (PAF) were randomized to PVI (n=78), 
ablation of the left atrial ganglionated plexi (GP) (n=82); 
or PVI+GP ablation (n=82). Freedom from PAF or atrial 
tachycardia (AT) was achieved in 44 (56%), 39 (48%), and 
61 (74%) patients in the PVI, GP, and PVI+GP groups, 
respectively (p=0.004). PVI+GP ablation compared with 
PVI alone was better (hazard ratio of 0.53; p=0.022). 
Fluoroscopy duration was 16+3 min, 20+5 min, and 23+5 
min for PVI, GP, and PVI+GP groups, respectively 
(p<0.001). Post-ablation atrial flutter was similar among 
groups (5-6%). No serious complications were reported. 
The authors concluded that addition of GP ablation to PVI 
confers a significantly higher success rate compared with 
either PVI or GP alone in patients with PAF (Katritsis D et 
al, J Am Coll Cardiol 2013;62:2318–2325). 
 
Relax-AHF Trial: Consistent Effects of Serelaxin 
Across All Subgroups of Patients With Acute Heart 
Failure  
The RELAX-AHF trial included 1161 patients 
(placebo, n = 580; serelaxin, n = 581). Subgroup analyses 
did not show any difference in the effects of serelaxin vs. 
placebo on dyspnea relief or on the incidence of 
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cardiovascular death or rehospitalizations for heart failure 
or renal failure at 60 days. The authors concluded that 
subgroup analyses of the RELAX-AHF trial has shown 
similar effects of serelaxin, when compared with placebo, 
across various subgroups, suggesting a consistency of the 
effect of serelaxin in the patients with acute heart failure 
(Metra M et al, Eur Heart J 2013; 34, 3128–3136).   
 
ORIGIN trial: Hypoglycemia Increases the Risk of 
Cardiovascular Events 
A total of 12,537 patients with dysglycemia and high 
cardiovascular (CV) risk were randomized to basal insulin 
glargine titrated to a fasting glucose of ≤5.3 mmol/L (95 
mg/dL) or standard glycemic care. Non-severe 
hypoglycemia was defined as symptoms plus glucose ≤54 
mg/dL and severe hypoglycemia if required assistance or 
glucose ≤36 mg/dL. During a median of 6.2 years, non-
severe hypoglycemic episodes occurred in 41.7% of 
glargine and 14.4% of standard care patients, while severe 
episodes occurred in 5.7% and 1.8%, respectively. Only 
severe hypoglycemia was associated with a greater risk for 
the primary outcome (CV death, MI or stroke) (HR: 1.58, 
P < 0.001), mortality (HR: 1.74; P < 0.001), CV death (HR: 
1.71; P < 0.001) and arrhythmic death (HR: 1.77; P = 
0.007). Similar findings were noted for severe nocturnal 
hypoglycemia for the primary outcome and mortality. The 
authors concluded that severe hypoglycemia is associated 
with an increased risk for CV outcomes in people at high 
CV risk and dysglycemia. Although the glargine group had 
an increased risk of hypoglycemia, the relative risk of CV 
outcomes with hypoglycemia was lower with insulin 
glargine-based therapy than with the standard glycemic 
control (ORIGIN Trial Investigators, Eur Heart J 2013; 
34, 3137–3144).  
 
Meta-Analysis: Patent Foramen Ovale Transcatheter 
Closure Superior to Medical Therapy on Recurrent 
Vascular Events Over a Mean Follow-up of 3.5 Years 
A meta-analysis was performed of 3 randomized 
studies (PC, CLOSURE I, and RESPECT trials) (N= 
2,303) of transcatheter (TC) closure of a patent foramen 
ovale (PFO) (n=1150) vs medical therapy (n= 1,153) in 
patients with cryptogenic stroke. Mean follow-up was 3.5 
years. Baseline characteristics were similar across studies. 
Intention-to-treat analyses showed a statistically 
significant risk reduction in stroke and/or transient 
ischemic attack in the TC PFO closure group when 
compared to medical treatment (pooled HR=0.59, P=0.04). 
The combined outcome of death, and vascular events, 
showed a borderline benefit for TC PFO closure when 
compared to medical treatment (HR=0.67, P=0.05). 
Subjects with a substantial PFO shunt tend to benefit the 
most with TC PFO closure (HR=0.35, P=0.06) (Rengifo-  
Moreno P et al, Eur Heart J 2013; 34, 3342–3352).  
 
Randomized Trial Comparing 3 Different Devices For 
Percutaneous Closure of a Patent Foramen Ovale 
(PFO): Significant Differences in the Neurological 
Event Rate Among Devices  
PFO closure was technically successful in all 660 
patients with cryptogenic stroke randomized to 3 different 
closure devices (Amplatzer, CardioSEAL-STARflex, and 
Helex occluder, n=220 per group). The procedure was 
complicated by cardiac tamponade requiring surgery in 1 
(Amplatzer group) and device embolization in 3 patients 
(Helex group). Thrombus formation on the device was 
detected in 12 cases (11 CardioSEAL-STARflex, 1 Helex, 
0 Amplatzer; P < 0.0001), of which 2 required surgery. 
Complete closure after single device implantation was 
more common with the Amplatzer and with the 
CardioSEAL-STARflex than with the Helex occluder. 
Within 5 years of follow-up, the primary endpoint 
(recurrent cerebral ischemia, i.e. stroke, transient ischemic 
attacks-TIA, or amaurosis fugax; death from neurological 
cause; or any other paradoxical embolism) occurred in 25 
patients (3.8%; 10 TIAs, 12 strokes and 3 cases of cerebral 
death). Compared with the CardioSEAL-STARflex (6%; 6 
TIAs, 6 strokes, 1 cerebral death) and Helex groups (4%; 
4 TIAs, 4 stroke, 1 cerebral death), significantly fewer 
events (P=0.04) occurred in the Amplatzer group (1.4%; 2 
strokes, 1 cerebral death). The authors concluded that 
procedural complications and long-term neurological 
event rates are low regardless of device used; however, the 
recurrent neurological event rate was significantly lower 
after Amplatzer implantation (Hornung M et al, Eur Heart 
J 2013; 34:3362–3369).   
 
Vascular Closure Devices Largely Reduce Vascular 
Complications Over Manual Closure Among Patients 
Having Percutaneous Coronary Intervention 
Of the 85,048 percutaneous coronary interventions 
(PCIs) performed in 32 hospitals in Michigan (2007-2009), 
28,528 (37%) procedures used vascular closure devices 
(VCDs). VCDs were associated with reductions in 
vascular complications (odds ratio-OR, 0.78; P=0.001) 
and postprocedure transfusions (OR, 0.85; P=0.011), 
except in patients with a body mass index (BMI) <25 
kg/m2 and those treated with platelet glycoprotein (GP) 
IIb/IIIa inhibitors. VCDs were associated with fewer 
hematomas (OR, 0.69; P<0.001) or pseudoaneurysms 
(OR, 0.54; P<0.001) but an increase in the odds of 
retroperitoneal bleeding (OR, 1.57; P=0.009). The authors 
concluded that VCDs were associated with a significant 
reduction in vascular complications and need for 
transfusion, albeit with no benefit when GP IIb/IIIa 
inhibitors were used and in those with normal or lean BMI; 
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there was a small increase in the more serious risk for 
retroperitoneal bleeding (Gurm HS et al, Ann Intern Med 
2013;159:660-666).  
 
Atrial Ectopy is a Predictor of Incident Atrial 
Fibrillation 
In 1260 adults without atrial fibrillation (AF) enrolled 
in the Cardiovascular Health Study (1989-1990), the 
premature atrial contraction (PAC) count was quantified 
by 24-hour Holter monitor. Doubling of the hourly PAC 
count was associated with a significant increase in AF risk 
(hazard ratio-HR, 1.17; P<0.001) and overall mortality 
(HR, 1.06; P<0.001). Compared with the Framingham 
model, PAC count alone resulted in similar AF risk 
discrimination at 5 and 10 years of follow-up and superior 
risk discrimination at 15 years. The addition of PAC count 
to the Framingham model resulted in significant 10-year 
AF risk discrimination improvement. The specificity for 
predicting AF at 15 years was >90% for PAC counts over 
32 beats/h. The authors concluded that the addition of PAC 
count to a validated AF risk algorithm provides superior 
AF risk discrimination and significantly improves risk 
reclassification (Dewland TA eta l, Ann Intern Med 
2013;159:721-728).  
 
SAVOR-TIMI 53 & EXAMINE Trials: the New 
Dipeptidyl Peptidase 4 (DPP-4) Inhibitors, Saxagliptin 
and Alogliptin, May not Have Serious Adverse 
Cardiovascular (CV) Effects  
In the SAVOR-TIMI 53 study, 16,492 patients with 
type 2 diabetes with history of, or at risk for, CV events 
were randomly assigned to receive saxagliptin or placebo. 
At 2 years, a primary end-point event (CV death, 
myocardial infarction-MI, or ischemic stroke) occurred in 
613 patients (7.3%) in the saxagliptin group and in 609 
patients in the placebo group (7.2%) (P=NS) The major 
secondary end point (CV death, MI, stroke, hospitalization 
for unstable angina, coronary revascularization, or heart 
failure) occurred in 1059 patients (12.8%) in the 
saxagliptin group and in 1034 patients in the placebo group 
(12.4%) (P=NS). More patients in the saxagliptin group 
(3.5%) than in the placebo group (2.8%) were hospitalized 
for heart failure (hazard ratio-HR, 1.27; P=0.007). Rates of 
pancreatitis were similar in the two groups (acute 
pancreatitis, 0.3% in the saxagliptin group and 0.2% in the 
placebo group; chronic pancreatitis, <0.1% and 0.1% in the 
two groups, respectively). The authors concluded that 
saxagliptin did not increase or decrease the rate of 
ischemic events, though the rate of hospitalization for heart 
failure was increased (Scirica BM et al, N Engl J Med 
2013; 369:1317-1326). 
 
In the EXAMINE study, a total of 5380 patients with 
type 2 diabetes and either an acute MI or unstable angina 
within previous 15-90 days underwent randomization to 
alogliptin or placebo and were followed for up to 40 
months (median, 18 months). A primary end-point event 
(CV death, MI or stroke) occurred in 305 patients assigned 
to alogliptin (11.3%) and in 316 patients assigned to 
placebo (11.8%) (HR, 0.96). Glycated hemoglobin levels 
were significantly lower with alogliptin than with placebo 
(mean difference, −0.36 percentage points; P<0.001). 
Incidences of hypoglycemia, cancer, pancreatitis, and 
initiation of dialysis were similar with alogliptin and 
placebo. The authors concluded that among patients with 
type 2 diabetes who had had a recent acute coronary 
syndrome, the rates of major adverse cardiovascular events 
were not increased with the DPP-4 inhibitor alogliptin as 
compared with placebo (White WB et al, N Engl J Med 
2013; 369:1327-1335).  
 
Hokusai-VTE Study: Edoxaban is Noninferior to 
Warfarin for the Treatment of Symptomatic Venous 
Thromboembolism and Causes Less Bleeding 
Patients with deep venous thrombosis (n=4921) or 
pulmonary embolism (n=3319), initially receiving heparin, 
were randomized to edoxaban at a dose of 60 mg or 30 mg 
(if creatinine clearance 30-50 ml/min or if weight <60 kg) 
once daily, or warfarin for 3-12 months. Among patients 
receiving warfarin, the time in the therapeutic range was 
63.5%. Edoxaban was noninferior to warfarin; the primary 
efficacy outcome (recurrent symptomatic venous 
thromboembolism) occurred in 130 patients in the 
edoxaban group (3.2%) and 146 patients in the warfarin 
group (3.5%) (hazard ratio-HR, 0.89; P<0.001 for 
noninferiority). The safety outcome (major or clinically 
relevant nonmajor bleeding) occurred in 349 patients 
(8.5%) in the edoxaban group and 423 patients (10.3%) in 
the warfarin group (HR, 0.81; P=0.004 for superiority). 
The rates of other adverse events were similar. A total of 
938 patients with pulmonary embolism had right 
ventricular dysfunction, as assessed by measurement of N-
T pro-BNP levels; the rate of recurrent venous 
thromboembolism in this subgroup was 3.3% in the 
edoxaban group and 6.2% in the warfarin group (HR, 
0.52). The authors concluded that edoxaban once daily 
after initial treatment with heparin was noninferior to 
standard therapy and caused significantly less bleeding in 
patients with venous thromboembolism, including those 
with severe pulmonary embolism (The Hokusai-VTE 
Investigators, N Engl J Med 2013; 369:1406-1415).  
 
ENGAGE AF-TIMI 48 Trial: in Patients with Atrial 
Fibrillation, Edoxaban was Equivalent to Warfarin for 
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Prevention of Thromboembolism but Had Lower Rates 
of Bleeding and Cardiovascular (CV) Death 
A total of 21,105 patients with moderate-to-high-risk 
atrial fibrillation (AF) were randomized to edoxaban, a 
direct oral factor Xa inhibitor (2 once daily regimens) or 
warfarin. At median follow-up of 2.8 years, the annualized 
rate of the primary end point (stroke or systemic 
embolism) was 1.50% with warfarin (median time in the 
therapeutic range, 68.4%), compared with 1.18% with 
high-dose edoxaban (hazard ratio-HR, 0.79; P<0.001 for 
noninferiority) and 1.61% with low-dose edoxaban (HR, 
1.07; P=0.005 for noninferiority). In the intention-to-treat 
analysis, there was a trend favoring high-dose edoxaban vs 
warfarin (HR, 0.87; P=0.08) and an unfavorable trend with 
low-dose edoxaban vs warfarin (HR, 1.13; P=0.10). The 
annualized rate of major bleeding was 3.43% with warfarin 
vs 2.75% with high-dose edoxaban (HR, 0.80; P<0.001) 
and 1.61% with low-dose edoxaban (HR, 0.47; P<0.001). 
The respective annualized rates of death from CV causes 
were 3.17% vs 2.74% (HR, 0.86; P=0.01), and 2.71% (HR, 
0.85; P=0.008), and rates of the key secondary end point (a 
composite of stroke, systemic embolism, or death from CV 
causes) were 4.43% vs 3.85% (HR, 0.87; P=0.005), and 
4.23% (HR, 0.95; P=0.32). The authors concluded that 
both once-daily regimens of edoxaban were noninferior to 
warfarin for prevention of stroke or systemic embolism 
and were associated with significantly lower rates of 
bleeding and CV death (Giugliano RP et al, N Engl J Med 
2013; 369:2093-2104).  
 
EUROMAX: Bivalirudin Started During Transport 
for Primary PCI, at 30 Days Reduced Major Bleeding 
but Increased Acute Stent Thrombosis 
A total of 2218 patients with STEMI transported for 
primary PCI were randomly assigned to receive either 
bivalirudin or unfractionated or low-molecular-weight 
heparin with optional glycoprotein IIb/IIIa inhibitors 
(control group). Bivalirudin reduced the risk of the primary 
outcome at 30 days (death or major bleeding) (5.1% vs. 
8.5%; relative risk-RR, 0.60; P=0.001) and secondary 
outcome (death, reinfarction or non-CABG major 
bleeding) (6.6% vs. 9.2%; RR, 0.72; P=0.02). Bivalirudin 
also reduced the risk of major bleeding (2.6% vs. 6.0%; 
RR, 0.43; P<0.001). The risk of acute stent thrombosis was 
higher with bivalirudin (1.1% vs. 0.2%; RR, 6.11; 
P=0.007). There was no significant difference in rates of 
death (~3%) or reinfarction (1.7% vs. 0.9%). The authors 
concluded that bivalirudin, started during transport for 
primary PCI, improved 30-day clinical outcomes with a 
reduction in major bleeding but with an increase in acute 
stent thrombosis (Steg PG et al, N Engl J Med 2013; 
369:2207-2217).  
 
ICAP Study: Added Colchicine Therapy Reduces Rate 
of Incessant or Recurrent Pericarditis  
A total of 240 patients with acute pericarditis were 
randomly assigned to receive colchicine (0.5 mg bid for 3 
months if weight >70 kg or 0.5 mg qd if weight ≤70 kg) or 
placebo in addition to conventional antiinflammatory 
therapy with aspirin or ibuprofen. The primary outcome 
(incessant or recurrent pericarditis) occurred in 20 patients 
(16.7%) in the colchicine group and 45 patients (37.5%) in 
the placebo group (relative risk reduction, 0.56; number 
needed to treat, 4; P<0.001). Colchicine reduced the rate of 
symptom persistence at 72 hours (19.2% vs. 40.0%, 
P=0.001), the number of recurrences per patient (0.21 vs. 
0.52, P=0.001), and the hospitalization rate (5.0% vs. 
14.2%, P=0.02). Colchicine also improved the remission 
rate at 1 week (85.0% vs. 58.3%, P<0.001). Overall 
adverse effects and rates of study-drug discontinuation 
were similar. No serious adverse events were observed. 
The authors concluded that in patients with acute 
pericarditis, colchicine, when added to conventional 
antiinflammatory therapy, significantly reduced the rate of 
incessant or recurrent pericarditis (Imazio M et al, N Engl 
J Med 2013; 369:1522-1528).  
 
Meta-Analysis: Influenza Vaccination Prevents 
Cardiovascular (CV) Events in High-Risk Patients 
A total of 6 randomized trials were analyzed (N=6735; 
mean age, 67 years; 51.3% women; 36.2% with a cardiac 
history; mean follow-up, 7.9 months), comparing 
influenza vaccine vs placebo or control, stratified by 
subgroups of patients with and without a history of acute 
coronary syndrome (ACS) within 1 year of randomization. 
Influenza vaccine was associated with a lower risk of 
composite CV events (2.9% vs 4.7%; relative risk-RR, 
0.64, P =0 .003). A treatment interaction was detected 
between patients with (RR, 0.45) and without (RR, 0.94) 
recent ACS (P for interaction = 0.02). The authors 
concluded that the use of influenza vaccine was associated 
with a lower risk of major adverse cCV events. The 
greatest treatment effect was seen among the highest-risk 
patients with more active coronary disease (Udell JA et al, 
JAMA 2013;310:1711-1720).  
 
Dose-Dependent Inverse Association Between Nut 
Consumption and Total Mortality & Major Causes of 
Death (Heart Disease/ Cancer/ Respiratory Diseases) 
The association between nut consumption and total and 
cause-specific mortality was examined among 76,464 
women in the Nurses' Health Study (1980–2010) and 
42,498 men in the Health Professionals Follow-up Study 
(1986–2010). During 3,038,853 person-years of follow-
up, 16,200 women and 11,229 men died. Nut consumption 
was inversely associated with total mortality among both 
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women and men and was dose-dependent (best hazard 
ratio 0.80 for those who ate nuts >7 times per week; 
P<0.001 for trend). Significant inverse associations were 
also observed between nut consumption and deaths due to 
cancer, heart disease, and respiratory disease. The authors 
concluded that the frequency of nut consumption was 
inversely associated with total and cause-specific 
mortality, independently of other predictors of death (Bao 
Y et al, N Engl J Med 2013;369:2001-2011). 
 
IABP-SHOCK II Trial: In Patients with Acute MI & 
Cardiogenic Shock Undergoing Revascularization, 
IABP did not Reduce 12-Month Mortality  
In the initial IABP-SHOCK II trial, the intra-aortic 
balloon pump (IABP) did not reduce 30 day mortality 
compared with control. Follow-up was continued for 12 
months. A total of 600 patients with cardiogenic shock 
complicating acute myocardial infarction (MI) who were 
undergoing early revascularization were assigned to IABP 
(n=301) or control (n=299). Of 595 patients completing 12 
month follow-up, 155 (52%) of 299 patients in the IABP 
group and 152 (51%) of 296 patients in the control group 
had died (relative risk -RR 1·01, p=NS). There were no 
significant differences in reinfarction (RR 2·60, p=0.05), 
recurrent revascularization (0.91, p=0·77), or stroke (1.50, 
p=NS). The authors concluded that in patients undergoing 
early revascularization for MI complicated by cardiogenic 
shock, IABP did not reduce 12 month all-cause mortality 
(Thiele H et al, The Lancet; 382(9905):1638 – 1645).  
 
CHAMPION Pooled Analysis: Cangrelor Reduced PCI 
Periprocedural Thrombotic Complications, at the 
Expense of Increased Bleeding 
Pooled analysis of data from 3 trials (CHAMPION-PCI 
/ CHAMPION-PLATFORM/ CHAMPION-PHOENIX) 
comparing cangrelor with control (clopidogrel or placebo) 
for prevention of thrombotic complications during and 
after PCI, included 24,910 patients undergoing PCI for 
STEMI (11.6%), non-ST-elevation acute coronary 
syndromes (ACS) (57.4%), and stable coronary artery 
disease (31%). Cangrelor reduced the primary outcome 
(death, MI, ischemia-driven revascularization, or stent 
thrombosis at 48 h) by 19% (3.8% for cangrelor vs 4.7% 
for control; odds ratio -OR 0.81, p=0.0007), and stent 
thrombosis by 41% (0.5% vs 0.8%, OR 0.59, p=0.0008). 
Benefits were maintained at 30 days. There was no 
difference in the primary safety outcome (severe bleeding) 
(0.2% in both groups), moderate bleeding (0.6% vs 0.4%), 
or in transfusion (0.7% vs 0.6%), but cangrelor increased 
mild bleeding (16.8% vs 13%, p<0.0001). The authors 
concluded that cangrelor reduced PCI periprocedural 
thrombotic complications, at the expense of increased 
bleeding (Steg PG et al, Lancet 2013; 382(9909):1981-92). 
 
Important Review and Other Articles  
Coronary artery revascularization in patients with diabetes 
(Armstrong EJ, et al, Circulation 2013; 128:1675-1685), 
Obesity in children & adolescents (Kelly AS, et al, Circulation 
2013; 128:1689-1712), Childhood obesity and cardiovascular 
dysfunction (Cote AT et al, J Am Coll Cardiol 2013;62:1309-
1319), 2013 ACCF/AHA Guideline for management of heart 
failure (Clyde WY et al, Circulation 2013;128:e240-e327; J Am 
Coll Cardiol 2013;62:e147-e239), Antithrombotic therapy 
during and after PCI in patients with AF (Verheugt FW, 
Circulation 2013;128:2058-2061), ICD leads (Swerdlow CD & 
Ellenbogen KA, Circulation 2013;128:2062-2071), Renal 
denervation for hypertension (Thukkani AK & Bhatt DL, 
Circulation 2013;128: 2251-2254;& Schlaich MP et al, J Am 
Coll Cardiol 2013,62:2031-2045), Peripheral arterial disease 
(Wennberg PW, Circulation 2013;128:2241-2250), Vitamin D 
& cardiovascular health (Lavie CJ et al, Circulation 
2013;128:2404-2406), CRT (Prinzen FW et al, Circulation 
2013;128:2407-2418), Role of vitamin D in atherosclerosis 
(Kassi E et al, Circulation 2013;128:2517-2531), Pulseless 
electric activity (Myerburg RJ et al, Circulation 2013;128:2532-
2541), Effects of external electrical and magnetic fields on 
pacemakers and defibrillators (Beinart R & Nazarian S, 
Circulation 2013;128:2799-2809), Managing antiplatelet 
therapy in coronary patients requiring surgery (Capodanno D & 
Angiolillo DJ, Circulation 2013;128:2785-2798), Targeting the 
PCSK9 for treatment of dyslipidemia (Urban et al, J Am Coll 
Cardiol. 2013;62:1401-1408), Treatment of obstructive 
thrombosed prosthetic heart valve (Huang G et al, J Am Coll 
Cardiol 2013;62:1731-1736), Colchicine and the heart 
(Deftereos S et al, J Am Coll Cardiol 2013;62:1817-1825), the 
MOGE(S) nomenclature system for cardiomyopathies 
(Arbustini E et al, J Am Coll Cardiol 2013;62:2046-2072), 
Antithrombotic treatment in TAVI (Rodés-Cabau J et al, J Am 
Coll Cardiol 2013;62:2349-2359), Pulmonary hypertension (J 
Am Coll Cardiol December 24, 2013, Vol. 62, No. 25_S), 2013 
ESC guidelines on the management of stable coronary artery 
disease (Montalescot G et al, Eur Heart J 2013;34: 2949-3003), 
ESC/EASD Guidelines on diabetes, pre-diabetes, and 
cardiovascular diseases (Rydén L, Eur Heart J 2013; 34:3035-
3087), Long QT syndrome (Schwartz PJ et al, Eur Heart J 2013; 
34: 3109-3116), Stabilization of atherosclerotic plaques (Ylä-
Herttuala S et al, Eur Heart J 2013; 34: 3251-3258), Brugada 
syndrome (Brugada et al, Eur Heart J 2013; 34: 3610-3615), 
Management of obstructive sleep apnea (Qaseem A et al, Ann 
Intern Medicine 2013; 159:471-483), Screening for primary 
hypertension in children and adolescents (Moyer VA et al, Ann 
Intern Medicine 2013; 159:613-619), Statins & cognitive 
function (Richardson K et al, Ann Intern Medicine 2013; 
159:688-697), Anemia in heart disease (Quaseem A et al, Ann 
Intern Medicine 2013; 159:770-779; & Kansagara T et al, Ann 
Intern Medicine 2013; 159:746-757), Circulatory shock 
(Vincent J-L & De Backer D, N Engl J Med 2013; 369:1726-
1734), β-blockers for hypertension (Wiysonge CS & Opie LH, 
JAMA 2013; 310:1851-1852), Inherited primary arrhythmia 
syndromes (Priori SG et al, Heart Rhythm 2013; 10: 1932-1963).  
